Literature DB >> 26914402

Type-II generalized family-wise error rate formulas with application to sample size determination.

Phillipe Delorme1, Pierre Lafaye de Micheaux1,2, Benoit Liquet3,4, Jérémie Riou5.   

Abstract

Multiple endpoints are increasingly used in clinical trials. The significance of some of these clinical trials is established if at least r null hypotheses are rejected among m that are simultaneously tested. The usual approach in multiple hypothesis testing is to control the family-wise error rate, which is defined as the probability that at least one type-I error is made. More recently, the q-generalized family-wise error rate has been introduced to control the probability of making at least q false rejections. For procedures controlling this global type-I error rate, we define a type-II r-generalized family-wise error rate, which is directly related to the r-power defined as the probability of rejecting at least r false null hypotheses. We obtain very general power formulas that can be used to compute the sample size for single-step and step-wise procedures. These are implemented in our R package rPowerSampleSize available on the CRAN, making them directly available to end users. Complexities of the formulas are presented to gain insight into computation time issues. Comparison with Monte Carlo strategy is also presented. We compute sample sizes for two clinical trials involving multiple endpoints: one designed to investigate the effectiveness of a drug against acute heart failure and the other for the immunogenicity of a vaccine strategy against pneumococcus.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  clinical research; multiple endpoints; multiple testing; r-power; sample size determination

Mesh:

Year:  2016        PMID: 26914402     DOI: 10.1002/sim.6909

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  6 in total

Review 1.  Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.

Authors:  Toshimitsu Hamasaki; Scott R Evans; Koko Asakura
Journal:  J Biopharm Stat       Date:  2017-10-30       Impact factor: 1.051

2.  A comparison of different antibiotic regimens for the treatment of infective endocarditis.

Authors:  Arturo J Martí-Carvajal; Mark Dayer; Lucieni O Conterno; Alejandro G Gonzalez Garay; Cristina Elena Martí-Amarista
Journal:  Cochrane Database Syst Rev       Date:  2020-05-14

3.  Graphical approaches for the control of generalized error rates.

Authors:  David S Robertson; James M S Wason; Frank Bretz
Journal:  Stat Med       Date:  2020-06-17       Impact factor: 2.373

4.  Acetyl-L-carnitine for patients with hepatic encephalopathy.

Authors:  Arturo J Martí-Carvajal; Christian Gluud; Ingrid Arevalo-Rodriguez; Cristina Elena Martí-Amarista
Journal:  Cochrane Database Syst Rev       Date:  2019-01-05

5.  Shift work, night work, and the risk of prostate cancer: A meta-analysis based on 9 cohort studies.

Authors:  Hong-Bing Du; Kai-Yun Bin; Wen-Hong Liu; Feng-Sheng Yang
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

6.  CPMCGLM: an R package for p-value adjustment when looking for an optimal transformation of a single explanatory variable in generalized linear models.

Authors:  Benoit Liquet; Jérémie Riou
Journal:  BMC Med Res Methodol       Date:  2019-04-16       Impact factor: 4.615

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.